Synthesis and antitumor activity of new derivatives of xanthen-9-one-4-acetic acid

Journal of Medicinal Chemistry

Volumn 45, Issue 22, 2002, Pages 4931-4939

  Gobbi, Silvia ^a   Rampa, Angela ^a   Bisi, Alessandra ^a   Belluti, Federica ^a   Valenti, Piero ^a   Caputo, Anna ^b   Zampiron, Antonella ^b   Carrara, Maria ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHEN 9 ONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; METHYL (2 METHYL 6 OXO 1,2 DIHYDRO 6H 3,11 DIOXACYCLOPENT[A]ANTHRACEN 10 YL)ACETATE; METHYL (2,2 DIMETHYL 6 OXO 1,2 DIHYDRO 6H 3,11 DIOXACYCLOPENT[A]ANTHRACEN 10 YL)ACETATE; METHYL (3,3 DIMETHYL 7 OXO 3H,7H 4,12 DIOXABENZ[A]ANTHRACEN 10 YL)ACETATE; METHYL 6 OXYXANTHEN 9 ONE 4 ACETATE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; XANTHEN 9 ONE 4 ACETIC ACID DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE;

ACETIC ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKOCYTES, MONONUCLEAR; MACROPHAGES, PERITONEAL; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES;

EID: 0037168054     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020929p     Document Type: Article

References (41)

1. Atassi, G.; Brief, P.; Berthelon, J. J.; Collanges, F. Synthesis and antitumor activity of some 8-substituted-4-oxo-4H-1-benzopyrans. Eur. J. Med. Chem. Chim. Ter. 1985, 20, 393-402.
2. Plowman, J.; Narayanan, V. L.; Dykes, D.; Szarvasi, E.; Briet, P.; Yader, O. C.; Paull, K. D. Flavone acetic acid: a novel agent with preclinical anti-tumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep. 1986, 70, 631-635.
3. Capolongo, L. S.; Balconi, G.; Ubezio, P.; Giavazzi, R.; Taraboletti, G.; Regonesi, A.; Yoder, O. C.; D'Incalci, M. Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. Eur. J. Cancer Clin. Oncol. 1987, 23, 1529-1535.
4. Kerr, D. J.; Kaye, S. B.; Cassidy, J.; Bradley, C.; Rankin, E. M.; Adams, L.; Setanoians, A.; Young, T.; Forrest, S.; Soukop, M.; Calvel, M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987, 47, 6776.
5. Bibby, M. C.; Double, J. A. Flavone acetic acid - from laboratory to clinic and back. Anti-Cancer Drugs 1993, 4, 3-17.
6. Smith, G. P.; Calveley, S. B.; Smith, M. J.; Baguley, B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumors. Eur. J. Cancer Clin. Oncol. 1987, 23, 1209-1211.
7. Bibby, M. C.; Double, J. A.; Loadman, P. M.; Duke, C. V. Reduction of tumor blood flow by flavone acetic acid: a possible componenet of therapy. J. Natl. Cancer Inst. 1989, 81, 216-220.
8. Ching, L. M.; Baguley, B. C. Induction of natural killer cell activity by the antitumor compound flavone acetic acid (NSC 347512). Eur. J. Cancer Clin. Oncol. 1987, 23, 1047-1050.
9. Ching, L. M.; Baguley, B. C. Enhancement of in vitro toxicity of mouse peritoneal exudate cells by flavone acetic acid. Eur. J. Cancer Clin. Oncol. 1988, 24, 1521-1525.
10. Baguley, B. C.; Calveley, S. B.; Crowe, K. K.; Fray, L. M.; O'Rourke, S. A.; Smith, G. P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumor necrosis factor alpha on colon 38 tumors in mice. Eur. J. Cancer Clin. Oncol. 1989, 25, 263-269.
11. Mace, K. F.; Hornung, R. L.; Wiltrout, R. H.; Young, H. A. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res. 1990, 50, 1742-1747.
12. Thomsen, L. L.; Ching, L. M.; Zhuang, L.; Gavin, J. B.; Baguley, B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 1991, 51, 77-81.
13. Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Calveley, S. B.; Denny, W. A. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J. Med. Chem. 1989, 32, 793-799.
14. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acid. J. Med. Chem. 1990, 33, 1375-1379.
15. Rewcastle, G. W.; Atwell, G. J.; Zhuang, L.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 1991, 34, 217-222.
16. Rewcastle, G. W.; Atwell, G. J.; Palmer, B. D.; Boyd, P. D. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 62. Structure-activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J. Med. Chem. 1991, 34, 491-496.
17. Ching, L. M.; Joseph, W. R.; Crosier, K. E.; Baguley, B. C. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res. 1994, 54, 870-872.
18. Patel, S.; Parkin, S. M.; Bibby, M. C. The effect of 5,6-dimethylxanthenone-4-acetic acid on tumor necrosis factor production by human immune cells. Anticancer Res. 1997, 17, 141-150.
19. Jameson, M. B.; Thompson, P. I.; Baguley, B. C.; Evans, B. D.; Harvey, V. J.; Porter, D. J.; McCrystal, M. R.; Kestell, P. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc. Am. Soc. Clin. Oncol. 2000, 19, 182a.
20. Candeias, L. P.; Everett, S. A.; Wardman, P. Free radical intermediates in the oxidation of flavone-8-acetic acid: possible involvement in its antitumor activity. Free Radical Biol. Med. 1993, 15, 385-394.
21. Everett, S. A.; Candeias, L. P.; Denny, W. A.; Wardman, P. Decarboxylation of the antitumour drugs flavone-8-acetic acid and xanthenone-4-acetic acid by nitrogen dioxide. Anti-Cancer Drug Des. 1994, 9, 68-72.
22. Harris, S. R.; Panaro, N. J.; Thorgeirsson, U. P. Oxidative stress contributes to the anti-proliferative effects of flavone acetic acid on endothelial cells. Anticancer Res. 2000, 20, 2249-2254.
23. Baguley, B. C. Small-molecule cytokine inducers causing tumor necrosis. Curr. Opin. Invest. Drugs 2001, 2, 967-975.
24. (a) Valenti, P.; Fabbri, G.; Rampa, A.; Bisi, A.; Gobbi, S.; Da Re, P.; Carrara, M.; Sgevano, A.; Cima, L. Synthesis and antitumor activity of some analogues of flavone acetic acid. Anti-Cancer Drug Des. 1996, 11, 243-252.
25. (b) Valenti, P.; Bisi, A.; Rampa, A.; Gobbi, S.; Belluti, F.; Da Re, P.; Carrara, M.; Cima, L. Synthesis of flavone-2′-carboxylic acid analogues as potential antitumor agents. Anti-Cancer Drug Des. 1998, 13, 881-892.
26. (c) Valenti, P.; Bisi, A.; Rampa, A.; Belluti, F.; Gobbi, S.; Zampiron, A.; Carrara, M. Synthesis and biological activity of some rigid analogues of flavone-8-acetic acid. Bioorg. Med. Chem. 2000, 8, 239-246.
27. Marverti, G.; Andrews, P. A. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulationdefective resistant cells. Clin. Cancer Res. 1996, 2, 991.
28. (a) Zinkewich-Peotti, K.; Andrews, P. A. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res. 1992, 52, 1902-1906.
29. (b) Andrews, P. A.; Albright, K. D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 1992, 52, 1895-1901.
30. Philpott, M.; Joseph, W. R.; Crosier, K. E.; Baguley, B. C.; Ching, L. M. Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br. J. Cancer 1997, 76, 1586-1591.
31. Yang, R. B.; Mark, M. R.; Gray, A.; Huang, A.; Xie, M. H.; Goddard, A.; Wood, W. I.; Gurney, A. L.; Godowski, P. J. Tolllike receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998, 395, 284-288.
32. Philpott, M.; Baguley, B. C.; Ching, L. M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 1995, 36, 143-148.
33. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 3666-3670.
34. Philpott, M.; Ching, L. M.; Baguley, B. C. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur. J. Cancer 2001, 37, 1930-1937.
35. Wright, S. D.; Ramos, R. A.; Tobias, P. S.; Ulevitch, R. J.; Mathison, J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249, 1431-1433.
36. Zhang, F. X.; Kirschning, C. J.; Mancinelli, R.; Xu, X. P.; Jin, Y.; Faure, E.; Mantovani, A.; Rothe, M.; Muzio, M.; Arditi, M. Bacterial lipopolysaccharide activates nuclear factor-kappa R through interleukin-1 signalling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem. 1999, 274, 7611-7614.
37. Mosmann, T. J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 1983, 65, 55.
38. Ching, L. M.; Finlay, G. J.; Joseph, W. R.; Baguley, B. C. In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. Eur. J. Cancer 1991, 27, 1684.
39. Patel, S.; Parkin, S. M.; Bibby, M. C. The effect of 5,6- dimethilxanthone-4-acetic acid on tumour necrosis factor production by human immune cells. Anticancer Res. 1997, 17, 141.
40. Garbin, F.; Eckert, K.; Immenschuh, P.; Kreuser, E. D.; Maurer, H. R. Prothymosin α1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. Int. J. Immunopharmacol. 1997, 19, 323-332.
41. Tallarida, R. J., Murray, R. B., Eds. Manual of Pharmacological Calculations with Computer Programs, 2nd ed.; Springer-Verlag: New York, 1987; p 153.